Clinical trial · no report yet · Phase 2
ICARUS-LUNG01
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
- NCT04940325 ↗
- Active not recruiting
- Gustave Roussy, Cancer Campus, Grand Paris
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase 2, Open Label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in Patients With Advanced and/or Unresectable Non-Small Cell Lung Cancer (NSCLC), With Biomarker Analysis to Characterize Response to Therapy
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Metastatic Lung Cancer; Advanced Non Small Cell Lung Cancer; Unresectable Non-small Lung Cancer
- Interventions
- DS-1062a
- Arms
- DS-1062a · Experimental
- Enrollment
- 100
- Primary outcomes
- Evaluation of objective response rate (ORR) based on investigator assessment
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris with Daiichi Sankyo
- Start
- May 12, 2021
- Primary completion
- Apr 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04940325 · updated Nov 26, 2025